Background
==========

Several health promoting effects have been attributed to the polyphenol resveratrol including anti cancer, anti-oxidant and anti-inflammatory activities.

Objective
=========

We investigated the effects of resveratrol on LAD2 and CD34^+^-derived mast cell activation in comparison to the known anti-allergy drug tranilast.

Methods
=======

Degranulation was quantified by β hexosaminidase assay, and cytokine, chemokine and cysteinyl leukotrienes (cysLT) expression was measured by real time PCR and ELISA. Fura-2 Ca^2+^ imaging was employed to measure \[Ca^2+^\]~i~.

Results
=======

In LAD2 cells, both resveratrol and tranilast (10 ug/ml) inhibited degranulation induced by mast cell activators IgE/anti-IgE (39% and 19%, respectively; P\<0.03), compound 48/80 (9% and 6%), and substance P (23% and 28%; P\<0.03). This may be attributable to modulation of Ca^2+^ levels, as resveratrol, and to a lesser extent tranilast, attenuated substance P-dependent increases in \[Ca^2+^\]~i~. Resveratrol and tranilast blocked cytokine formation, reducing substance P-induced TNF production (65%; P=0.04 and 46%; P=0.09, respectively), but not MCP-1 production. Furthermore, resveratrol inhibited FcepsilonRI mediated production of cysLT by 31% compared to control, whereas tranilast had no effect. The effects of resveratrol on degranulation and release of cysLT were more marked in human primary mast cells (HuMC) (64% and 90% inhibition, respectively; P\<0.05), and the polyphenol was found to be significantly more efficacious than tranilast in these cells.

Conclusions
===========

Resveratrol inhibited mast cell function at the level of degranulation, and cytokine and cysLT production, and was comparable, and in some cases, more potent than the anti-allergy drug tranilast. Thus resveratrol may be an effective therapeutic agent for the treatment of allergic disease.
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